No conviction changes recorded
Upgrade to premium to see the full reasoning behind each conviction change.
Sign in to unlockFair Value Distribution — percentile bands
0.0% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
15.0%/yr
±7.5% · revenue growth to justify current price
FCF-Based Reverse DCF
63.0%/yr
±4.4% · FCF growth to justify current price
THE GAP
Market pricing margin compression or rising capex
Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.
Sign in to unlockDuPont materials science transformation; semiconductor/water filtration growth segments.
Specialty chemicals demand tied to industrial capex cycle; divestiture execution risk.
Major transformation year completed: Qnity spin-off done, Aramids sale pending Q1 2026. Focus now pure-play healthcare/water + industrials. PFAS/litigation overhang remains material. Healthcare segmen...